Six-year follow-up data from the SEQUOIA trial showed that zanubrutinib provided durable PFS and strong long-term outcomes in treatment-naïve CLL/SLL.
Pharmacists lead antifungal and antibiotic stewardship beyond hospitals, using rapid diagnostics, vaccines, and equity to curb resistance.
Pharmacists must balance the lifesaving automation of advanced technology with the harsh reality of a high-cost, high-risk transition.
Pharmacists can counter misinformation on SSRIs with evidence-based antidepressant guidance, safe tapering advice, and patient-centered depression care.
Pharmacy technicians are vital to obesity care, improving access, adherence, and patient engagement in increasingly complex treatment pathways.
A landscape overview of enfortumab vedotin’s expanding role across bladder cancer settings—from MIBC to earlier lines of therapy—with a focus on pharmacist-led patient support, AE management, and real-world implementation.
Darren Triller, PharmD, walks through the relative ease and impact of each of the 5 ADAPT priority areas, makes the case for dashboard-driven population health management.
Efficacy and safety were evaluated in the phase 3 IMvigor011 trial.
Clinical pharmacists Andrew Willeford and Laura Velazquez explore the paradigm shift in oHCM management, highlighting best practices for pharmacist-led clinical workflows in health-system practice.
Neoadjuvant pembrolizumab in colorectal cancer delivers durable, relapse-free outcomes presurgery, with ctDNA blood tests helping to predict responders.
Maroney discussed the pharmacist’s role in patient education, safe medication management, and incorporating broader treatment strategies into individualized mental health care plans.
FDA Recall targets True Metrix blood glucose monitoring systems after E-5 errors risk mistreating diabetes; updated guidance helps patients, pharmacists prevent harm.
A single dose of psilocybin produced rapid and clinically meaningful reductions in depressive symptoms in patients with major depressive disorder.
FDA approves benralizumab for hypereosinophilic syndrome, driven by NATRON phase 3 clinical trial data showing fewer flares and improved fatigue.
The ruling comes after weeks of uncertainty for patients, health care providers, and pharmacists about how and whether they could access and distribute the drug.
Laughing gas misuse is surging as nitrous oxide drug abuse spreads online
Phase 3 SCORPIO-PEP trial shows ensitrelvir cuts symptomatic COVID-19 after household exposure, boosting postexposure prophylaxis options for high-risk patients.
This week’s episode covers Marty Makary’s resignation as FDA commissioner, evolving hepatitis B vaccination efforts, and new FDA approvals in asthma and precision oncology.
Neurology pharmacists drive safer medication changes, boost access and financial assistance, and deliver major cost savings through high-impact outpatient pharmacist intervention.
HBV still threatens health workers as vaccination programs stall; learn how managers and pharmacists can boost coverage with digital tracking.
Securing executive buy-in, building multidisciplinary coalitions, and targeting inappropriate antiplatelet use are among the most critical steps in implementing antithrombotic stewardship programs.
Data from a phase 1/2 trial revealed that CRISPR–Cas9–edited donor stem cell transplants lacking CD33 enabled rapid engraftment and allowed posttransplant gemtuzumab ozogamicin maintenance in high-risk patients with AML/MDS without prolonged hematologic toxicity.
A novel urine-based test outperformed mpMRI in detecting prostate cancer progression and may help reduce unnecessary biopsies.
Patients with CKD and GERD who initiated P-CABs had a 37% lower risk of needing renal replacement therapy.
Emerging evidence supports the use of psilocybin in palliative care, yet Schedule I status uniquely limits access outside of clinical trials in the US.
Data from the STEP UP trial support semaglutide 7.2 mg as a well-tolerated option for patients who need greater weight reduction.
Pharmacists can guide the appropriate use of nonprescription therapies, reinforce recommended prevention strategies, and encourage patients to seek medical evaluation when warranted.
FDA approval brings the first all-oral AML combination therapy, decitabine/cedazuridine with venetoclax, for older or unfit patients, cutting clinic visits.
Phase 1b data show zongertinib delivers durable first-line responses in HER2-mutant NSCLC, including brain metastases, with manageable safety.
The commissioner's sudden departure leaves the agency navigating a crowded agenda of unresolved policy questions—many with direct implications for pharmacists and their patients.
